Greig, Jenny A.
Martins, Kelly M.
Breton, Camilo
Lamontagne, R. Jason http://orcid.org/0000-0002-9068-3348
Zhu, Yanqing
He, Zhenning
White, John
Zhu, Jing-Xu
Chichester, Jessica A. http://orcid.org/0000-0001-7879-120X
Zheng, Qi http://orcid.org/0000-0002-2582-1222
Zhang, Zhe
Bell, Peter
Wang, Lili http://orcid.org/0000-0001-9347-3939
Wilson, James M. http://orcid.org/0000-0002-9630-3131
Funding for this research was provided by:
This work was supported by Amicus Therapeutics, Passage Bio, and Ultragenyx.
Article History
Received: 9 March 2022
Accepted: 29 August 2023
First Online: 6 November 2023
Competing interests
: J.M.W. is a paid advisor to and holds equity in iECURE, Scout Bio, Passage Bio and the Center for Breakthrough Medicines (CBM). J.M.W. also holds equity in the former G2 Bio asset companies and has sponsored research agreements with Amicus Therapeutics, CBM, Elaaj Bio, FA212, former G2 Bio asset companies, iECURE, Passage Bio and Scout Bio, which are licensees of Penn technology. J.A.G., C.B., L.W. and J.M.W. are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments. All other authors have no competing interests.